Effect of exercise training on A‐FABP, lipocalin‐2 and RBP4 levels in obese women

Choi, Kyung Mook; Kim, T. N.; Yoo, Hye Jin; Lee, K. W.; Cho, Geum-Joon; Hwang, Taik Gun; Baik, Sei-Hyun; Choi, Dong Seop; Kim, Seon Mee

doi:10.1111/j.1365-2265.2008.03374.x

Cited by 94 publications

(105 citation statements)

References 28 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Choi et al found that lipocalin-2 concentrations did not differ between obese and normal weight women. Exercise training and weight loss did not affect lipocalin-2 or the well-established inflammatory marker hs-CRP [27]. Due to its autocrine or paracrine effects, lipocalin-2 antagonised the inflammatory effects of TNF-a in macrophages [8,14].…”

Section: Prace Oryginalnementioning

confidence: 90%

Związek między stężeniami lipokaliny-2 i testosteronu wolnego w zespole policystycznych jajników

Yılmaz¹,

Temür²,

Çalan

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

Introduction: Lipocalin-2 is an adipokine that is mainly produced from adipocytes and macrophages. Data related to PCOS and other obesity-associated disorders have shown divergent results. Here, we studied lipocalin-2 concentrations in women with PCOS and in healthy women, and investigated the potential contributors underlying lipocalin association with PCOS. Material and methods: Forty-four women with PCOS and 47 age-and BMI-matched healthy women were enrolled. Fasting serum glucose, insulin, homeostasis model assessment of insulin resistance (HOMA-IR), high-sensitivity C-reactive protein (hs-CRP), and free testosterone levels were measured. The body fat percentage was measured by bioelectrical impedance. Results: Lipocalin-2 concentrations were significantly higher in the PCOS group than in the control group (55.74 ± 17.54 ng/mL vs. 36.46 ± 19.62 ng/mL, p = 0.011). There was a correlation between lipocalin-2 levels and free testosterone. In a multiple regression model, the body fat percentage, HOMA-IR, and hs-CRP were not associated with lipocalin-2. However, only free testosterone was associated with lipocalin-2. A "lipocalin-2 = 11.214 + (1.943 × free-testosterone)" equation was obtained. Conclusions: Serum lipocalin-2 levels were higher in women with PCOS, and only free testosterone was associated with lipocalin-2. Lipocalin-2 levels and their influencing factors have discrepant results in both PCOS and other obesity-or insulin resistance-related metabolic disorders. Thus, the potential role of lipocalin-2 in PCOS should be clarified. (Endokrynol Pol 2017; 68 (1): 7-12)

show abstract

Section: Prace Oryginalnementioning

confidence: 90%

Związek między stężeniami lipokaliny-2 i testosteronu wolnego w zespole policystycznych jajników

Yılmaz¹,

Temür²,

Çalan

et al. 2017

Endokrynologia Polska

View full text Add to dashboard Cite

show abstract

“…One study using visceral fat from obese subjects did confirm lipocalin 2 mRNA expression in this tissue, but subcutaneous fat tissue was not studied (10). Interventional studies looking at the effect of weight loss, which is known to improve insulin sensitivity, have mostly found no change in lipocalin 2 levels with weight loss (18,19), although a recent study did find a reduction in women with polycystic ovary syndrome (PCOS) (20). Despite the significant correlation between lipocalin 2 and HOMA-IR at baseline when adjusting for anthropometric measurements, this correlation disappears after also adjusting for serum creatinine.…”

Section: Discussionmentioning

confidence: 99%

Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study

Liu

Hamnvik

Petrou

et al. 2011

European Journal of Endocrinology

View full text Add to dashboard Cite

Objective: Lipocalin 2 (LCN2 or NGAL), a protein derived from neutrophils, macrophages, adipocytes, and other cells, has been proposed to be a link between obesity and insulin resistance (IR), but animal and cross-sectional human studies have revealed conflicting results. We studied the association of serum lipocalin 2 with anthropometric, metabolic, and cardiovascular risk markers in young healthy men cross-sectionally and, for the first time, prospectively after 2 years of follow-up, with and without adjustment for potential confounders including serum creatinine. Design: Two hundred and seventy-two participants were randomly selected from the Cyprus Metabolism Study (1056 men, 18 years), of whom 93 subjects participated in the follow-up study 2 years after baseline assessment. Associations were also explored between total and free leptin levels (to serve as positive controls) and anthropometric metabolic variables. Results: In the cross-sectional study, lipocalin 2 levels were marginally correlated in the unadjusted model with central fat distribution but not with body weight or total body fat mass. After adjusting for age, smoking, activity, body mass index, fat percentage, waist-to-hip ratio, and serum creatinine, no correlation was found with any cardiovascular risk factor. There was no correlation with the homeostasis model assessment of IR (HOMA-IR) at baseline. In the prospective analyses, baseline levels of lipocalin 2 were not predictive of any variables in unadjusted or adjusted models. As expected, total and free leptin were associated with anthropometric and metabolic variables both cross-sectionally and prospectively. Conclusions: We demonstrate that lipocalin 2 is not an independent predictor of metabolic and cardiovascular risk factors in young men cross-sectionally or prospectively.

show abstract

“…Interventional studies on circulating AFABP Several interventional studies have evaluated the influence of weight reduction and statin use on circulating AFABP (Table 3). All [81][82][83] except one [84] published studies have demonstrated that the serum AFABP level is reduced following successful weight reduction through lifestyle or surgical measures. Furthermore, atorvastatin treatment over 3 months has been found to significantly decrease circulating AFABP levels in statin-naive participants with atherosclerosis [85], in agreement with in vitro findings [57].…”

Section: Controlsmentioning

confidence: 99%

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

2012

View full text Add to dashboard Cite

Adipocyte fatty acid binding protein (AFABP, also known as aP2 and FABP4) has recently been introduced as a novel fat-derived circulating protein. AFABP serum concentrations are positively correlated with markers of the metabolic syndrome and vascular disease in various cross-sectional and interventional studies. Furthermore, a small set of prospective studies indicates that high AFABP serum levels at baseline predict the risk for metabolic and vascular morbidity and mortality. Studies in Afabp (also known as Fabp4) knockout mice and AFABP inhibitortreated animals suggest that total AFABP promotes insulin resistance, hypertriacylglycerolaemia and atherosclerosis by ligand/ligand delivery, as well as ligand-independent mechanisms. In contrast, the pathophysiological significance of circulating AFABP and the mechanisms leading to its release remain to be established. The current review summarises recent findings on the regulation and potential role of AFABP in metabolic and vascular disease.

show abstract

Effect of exercise training on A‐FABP, lipocalin‐2 and RBP4 levels in obese women

Abstract: Exercise training with weight loss induced a significant reduction in circulating A-FABP levels in obese Korean women.

Cited by 94 publications

References 28 publications

Związek między stężeniami lipokaliny-2 i testosteronu wolnego w zespole policystycznych jajników

Związek między stężeniami lipokaliny-2 i testosteronu wolnego w zespole policystycznych jajników

Circulating lipocalin 2 is associated with body fat distribution at baseline but is not an independent predictor of insulin resistance: the prospective Cyprus Metabolism Study

Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?

Contact Info

Product

Resources

About